CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗后 18F-FDG PET/CT 检测到的淋巴瘤早期超进展
英文原题：Early Hyperprogression of Lymphoma Detected by 18 F-FDG PET/CT After Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
Early Hyperprogression of Lymphoma Detected by 18 F-FDG PET/CT After Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
18F-FDG PET/CT 在淋巴瘤的分期、治疗监测和预后评估中发挥重要作用。一名 65 岁女性难治性大 B 细胞淋巴瘤患者在接受CAR-T 细胞治疗 35 天后进行了 18F-FDG PET/CT 显像。图像显示左侧上颌病变进展，并额外累及左侧面部皮下组织。左侧面部病变的病理检查诊断为淋巴瘤早期超进展。
展开英文摘要原文
18 F-FDG PET/CT plays important roles in the staging, treatment monitoring, and prognostic assessment of lymphoma. A 65-year-old woman with refractory large B-cell lymphoma underwent 18 F-FDG PET/CT imaging 35 days after a chimeric antigen receptor T-cell therapy. The images showed progression of the left maxillary lesion and additional involvement of the left facial subcutaneous tissue. Pathological examination of the left facial lesion led to a diagnosis of early hyperprogression of lymphoma.
论文信息
- 作者
- He L、Deng Y、Deng Y、Xie H、Zhang W
- 单位
- From the Departments of Nuclear Medicine.
- 文献类型
- 病例报告
- 期刊
- Clinical nuclear medicine2023 Mar 1
- 原文标识
- PubMed 36634320 · DOI 10.1097/RLU.0000000000004543